Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
Fosun International's stock has tumbled over 14% in the last 90 days, reigniting the debate over the Chinese conglomerate's true worth. With shares trading at HK$4.12 against a widely cited fair value of HK$5.77, analysts are divided on whether this is a moment of market overreaction or a sign of deeper structural challenges.
After a prolonged downturn, the pre-owned watch market saw a modest rebound in late 2025, driven largely by Patek Philippe and Rolex. However, a new report reveals a stark divide, with most brands still struggling with value retention as consumers pivot towards pragmatic purchases.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
German biotech firm AMSilk partners with Italian mill Pure Denim to launch a new category of high-performance, sustainable denim infused with lab-grown spider silk proteins, targeting the luxury market with enhanced comfort and eco-credentials.
AIGH Capital Management has liquidated its entire position in semiconductor firm MaxLinear, a move that coincides with the chipmaker's recent strong quarterly earnings report, raising questions about the fund's strategy.
Tesla's stock dipped amid reports of potential Ford-Xiaomi joint venture talks, highlighting growing competitive pressures from Chinese EV makers and the complex geopolitical landscape shaping the auto industry's future.
The Hershey Company is expanding its Jolly Rancher brand with a dual-pronged strategy: launching spicy 'Heat Wave' gummies and a limited-edition collectible box in partnership with VeeFriends. This move aims to capture the attention of younger consumers and digital-native collectors, signaling a shift in the confectionery giant's growth playbook beyond traditional chocolate.
Finnish cargo handling giant Kalmar Oyj partners with Tata Consultancy Services to build an AI-powered digital core, aiming to boost operational efficiency and solidify its long-term service offerings in the global ports sector.
While October's COLA announcement brings temporary relief, a growing body of evidence suggests the formula used to calculate Social Security adjustments fails to reflect the real-world expenses of retirees, creating a persistent and compounding budget gap.
Albertsons' retail media division opens its first NYC office and unveils a new logo, signaling a significant expansion and strategic push to deepen ties with advertisers and agencies in the competitive retail media landscape.
Snowflake announces a strategic $200 million partnership with OpenAI to integrate its AI models natively into the data cloud platform. The move aims to let enterprises query and analyze proprietary data using natural language, intensifying competition in the AI-infused data management sector.
The grocery sector begins 2026 with significant executive turnover, including leadership changes at Lidl US, The Save Mart Companies, and a major realignment within Walmart's top ranks ahead of its CEO transition.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
